Cooley advised Oyster Point Pharma on the deal, while Cravath represented Viatris. Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, announced its definitive agreement to be acquired...
This content is for Standard 1 Year members only. LoginJoin Now